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Abstract 
The alarming rate at which pathogens are becoming resistant to conventional therapies 
is a reason for the urgent need to develop alternative strategies to combat bacterial 
infections. MGN-3 (biobran) was discovered and named after the three scientists: 
Maeda, Ghoneum and Ninomiya. It is an enzymatically modified rice bran arabinoxylan, 
which can enhance the host immune system by mediating macrophage function. The 
aim of this study was to investigate the effect of MGN-3 on the clearance of methicillin-
resistant Staphylococcus aureus (MRSA) by human U937 macrophages. The uptake of 
MGN-3 by U937 macrophages was measured by a phloroglucinol colorimetric assay and 
visualised by confocal microscopy. An in vitro host-pathogen assay (n=24) was 
performed following exposure of macrophages to MGN-3 (0.5 to 2.0 mg/ml) and/or 
lipopolysaccharide (LPS) at 1.0 µg/ml or 5.0 µg/ml for 24 hours. The assay was repeated 
in the presence of receptor inhibitors, to identify potential molecular mechanisms of 
action. Bacterial internalisation by U937 macrophages was visualised by scanning 
electron microscopy (SEM). 
The study demonstrated approximately 29% of total available MGN-3 was taken up by 
U937 macrophages. There was a significant (P<0.05) dose-dependent increase in 
clearance of MRSA by U937 macrophages in the presence of MGN-3 compared to the 
negative control. SEM confirmed internalisation of MRSA by U937 macrophages 
following MGN-3 treatment. However, MGN-3 inhibited LPS-induced phagocytosis, 
suggesting both polysaccharides may compete as ligands for the same receptor(s) but 
that LPS is more potent at inducing phagocytosis. TLR-4 and dectin-1 receptor inhibition 
reversed the effects of MGN-3 or LPS treatment, suggesting both MGN-3 and LPS 
mediate phagocytosis at least in part through these receptors.  
In conclusion, this study established that MGN-3 significantly promotes phagocytosis of 
MRSA by U937 macrophages in a dose-dependent manner via TLR-4 and dectin-1. 
Moreover, MGN-3 mediated LPS-induced phagocytosis, suggesting competition for the 
same receptor(s) and highlighting the potential of MGN-3 to modulate excessive LPS-
induced pro-inflammatory responses. Collectively, these findings may ultimately lead to 
novel potential therapeutic strategies that can be used alongside antibiotic treatments 
to combat MRSA infection, thereby reducing the over reliance on antibiotic usage.  
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1. Introduction 
 
1.1 Dietary fibre  
Naturally, dietary fibre is present in various foods such as vegetables, cereals and nuts 
(Dhingra et al., 2012). It is a complex carbohydrate composed of soluble and insoluble 
fibre (Zhang et al., 2016b). Dietary fibre is analogous carbohydrates or edible plant 
materials, which are fermented partially or completely within the large intestine, but 
resistant to hydrolysis in humans by the small intestines (Li and Komarek, 2017). Short 
chain fatty acids, which are linked to anti-carcinogenic activity, are produced after 
fermentation (Lattimer and Haub, 2010).  
Components of dietary fibre include polysaccharides, oligosaccharides, lignin, pectin, 
cellulose, hemicellulose, waxes and gums (Dhingra et al., 2012). Dietary fibre is typically 
broken down into two main categories, with differing physiological properties based on 
water solubility (Li and Komarek, 2017). Soluble fibre such as pectin and pentosans can 
regulate blood glucose, lower cholesterol and postpone gastric emptying, whilst 
insoluble fibre such as cellulose and lignin can encourage intestinal flora proliferation 
and increase laxation (Dai and Chau, 2017; Li and Komarek, 2017). 
Hemicelluloses are cell wall polysaccharides that contain b-1, 4 glucosidic linkages, 
bound to glucose unit backbones (Dhingra et al., 2012). Within its structure is a variety 
of sugars, most commonly, arabinose, xylose and mannose (Dhingra et al., 2012). 
Nutrients such as vitamins and minerals are sourced from dietary fibre and whole grains, 
along with phytochemicals such as b-glucan, inulin and phenolics (Lattimer and Haub, 
2010). 
Consumption of dietary fibre is associated with improved human health, including 
reduced risk of cardiovascular disease, type 2 diabetes mellitus and colon cancer 
(Mendis et al., 2016) 
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1.2 Gastrointestinal (GI) physiology 
The gastrointestinal (GI) tract functions to absorb nutrients from foods, following a 
series of digestive processes such as mechanical breakdown and salivary and gastric 
enzyme secretion (Peate, 2018). The small intestine is the main area of absorption, in 
which digestible macronutrient subunits, micronutrients, vitamins and minerals are 
absorbed. The large intestine is primarily involved in water and microfloral metabolite 
uptake, including uptake of ammonia, urea and short chain fatty acids, and remaining 
nutrients (usually at low levels) (Brownlee, 2011).  
 
 
Figure 1: The gut-associated lymphoid tissue (GALT). Epithelial boarder between immune cells, Peyer’s Patches and 
mesenteric lymph nodes etc. and the intestinal lumen (Mendis et al., 2016). 
 
 GI immune function 
The GI mucosa acts as a barrier, keeping bacteria, toxins and digestive enzymes from 
interaction with the rest of the body (Kim et al., 2010).  Tolerance to benign 
microorganisms by the gut-associated lymphoid tissue (GALT) is vital for homeostasis 
(Brownlee, 2011). The GALT (Figure 1) encompasses the Peyer’s Patches (PP), lamina 
propria and mesenteric lymph nodes that contain dendritic cells and lymphocytes 
(Kiyohara et al., 2010). The follicle-associated epithelium (FAE) surrounds aggregated 
lymphoid tissues to give rise to the PP (in the small intestine) (Jung et al., 2010). Chronic 
inflammatory disorders can be a result of loss of tolerance, leading to conditions such 
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as Crohn’s and coeliac disease (Bain and Mowat, 2014). Immunosenescence is also 
associated with decreased or loss of tolerance (Kobayashi et al., 2013). 
M (microfold) cells are specialised enterocytes, contained within the FAE, along with an 
abundance of infiltrated macrophages, dendritic cells (DCs) and B- and T- cells. 
Transcytosis of bacteria and antigens by M cells, to underlying immune cells and PP 
sampling can either initiate or inhibit an immune response. However, PP are also a 
possible point of systemic entry for pathogens. Several bacterial species, such as 
Escherichia coli and Salmonella typhimurium are able to gain systemic access via 
adherence to M cells (Jung et al., 2010).  
The protective potential of the colonic mucosal barrier appears to be increased by 
various types of dietary fibre, including wheat bran and alginate. Dietary fibre has been 
suggested to reduce the number of potentially harmful metabolites (Brownlee, 2011). 
It has been proposed that M cells are able to transport dietary fibre to the underlying 
immune cells, through the PP to activate local cytokine production (Volman et al., 2008; 
Mendis et al., 2016). 
 
1.3 Systemic immune function 
The initial protection provided by the innate immune system is via epithelial barriers, 
the lining of the gastrointestinal and urinary tract and the skin (Volman et al., 2008). 
Leukocytes involved in the acute stages of innate immunity include macrophages, 
neutrophils and natural killer (NK) cells (Volman et al., 2008).  
Complement is involved in pathogen defence, inflammation and maintenance of 
homeostasis as part of the innate immune system (Merle et al., 2015). Complement 
activation occurs immediately after pathogen encounter and is initiated through either 
classical, alternative or mannose-activated pathways (Merle et al., 2015; Silawal et al., 
2018). In addition to its involvement in innate immunity, T cell, B cell and antigen 
presenting cell (APC) function is regulated by complement (Wills-Karp, 2007). 
Adaptive immunity can be activated by interaction with the innate immune system 
(Mendis et al., 2016). Adaptive immunity is highly specific, with slower initiation 
compared to the non-specific innate immunity (Volman et al., 2008). Once activated, B-
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lymphocytes produce antigen specific antibodies, which upon repetitive interaction with 
the same antigen, responses are enhanced (Volman et al., 2008). Cytotoxic and helper 
T-lymphocytes are involved in cell lysis and cytokine production respectively (Volman et 
al., 2008).  
 
 Inflammation 
Inflammation is a tightly regulated protective immune response to potentially harmful 
stimuli (Guo et al., 2015). Acute inflammation is an immediate local response to 
infection or tissue damage, usually lasting hours or days (Peate, 2011). Acute 
inflammation presents as pain, swelling, redness, heat and impaired function (Peate, 
2011). Chronic inflammation, on the other hand, usually causes a dampened, constant 
response, ultimately leading to tissue damage (Franceschi and Campisi, 2014). 
Persistent pathogen infection can be a result of insufficient inflammation (Guo et al., 
2015).  
Inducers of inflammation (Figure 2) include pathogen associated molecular patterns 
(PAMPs) which are microbial surface molecules that are targeted by the innate immune 
system and damage-associated molecular patterns (DAMPs) which are released from 
damaged host cells (Mendis et al., 2016; Varela et al., 2018). Mannose and toll-like 
receptors (TLRs), for example, are pattern recognition receptors (PRRs) able to 
distinguish PAMPs (Mendis et al., 2016). Activation of TLRs subsequently stimulates 
protein kinase recruitment and activation, followed by the activation of transcription 
factors such as interferon response factor-3 (IRF-3) and nuclear factor kB (NF-kB), 
leading to enzyme, protein and cytokine transcription (Mendis et al., 2016). The 
inflammatory cytokines that are released include interleukin-1 (IL-1), interleukin-6 (IL-6) 
and tumour necrosis factor alpha (TNFa) (Varela et al., 2018). During this process, an 
inflammatory response is initiated, followed by resolution and repair (Italiani and 
Boraschi, 2014).  
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Figure 2: The inflammatory process (Varela et al., 2018). The diagram shows the process of inflammation starting 
from pathogen associated molecular patterns (PAMPs) and damage associated molecular patterns (DAMPs) receptor 
stimulation and how the five signs of inflammation occur.  
  
Neutrophils are the first cells present during an inflammatory response, they recruit 
monocytes to the area via chemoattractants (Varela et al., 2018). Both neutrophils and 
macrophages synthesise reactive oxygen species (ROS) after stimulation (Varela et al., 
2018). 
A crucial component of the innate system and inflammation is the activation of an 
inflammasome, which are multimeric complexes (Sharma and Kanneganti, 2016). 
Formation of the inflammasome is facilitated by intracellular ROS (Varela et al., 2018). 
Inflammasomes essentially causes caspase-1 activation to induce pyroptosis 
(inflammatory cell death) via production of interleukin-18 (IL-18) and interleukin-1 beta 
(IL-1b) (Sharma and Kanneganti, 2016).  
Anaphylatoxins such as complement 3a (C3a) and complement 5a (C5a) in the 
complement cascade, can stimulate inflammation by initiating an oxidative burst in 
neutrophils and macrophages (Merle et al., 2015). C3a also shows anti-inflammatory 
properties in some cells (Merle et al., 2015). 
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 Monocytes and Macrophages 
Circulating blood monocytes are precursors of macrophages and represent ~10% of 
leukocytes in the human body, whilst macrophages constitute 10-15% of total cell 
counts in normal conditions, with numbers peaking during an inflammatory response 
(Italiani and Boraschi, 2014). Monocytes are heterogenous cells, with the ability to 
differentiate into macrophages and dendritic cells as they exit the vascular endothelium 
via diapedesis, in the presence of infection (Yang et al., 2014; Boyette et al., 2017). They 
provide innate host defences in the form of pathogen recognition, phagocytosis, 
production of nitric oxide (NO), ROS, inflammatory cytokines and myeloperoxidase 
(Italiani and Boraschi, 2014; Fang et al., 2017). Macrophages are one of the major cell 
types involved during pathogen encounter and inflammation (Ginhoux and Jung, 2014). 
Wound healing, debris clearance, immune surveillance, pathogen defence and 
inflammatory response induction and resolution are the collective functions of tissue 
macrophages (Italiani and Boraschi, 2014). 
Uncommitted (M0) macrophages can be polarised to pro- and anti-inflammatory 
phenotypes, known as M1 and M2 macrophages respectively (Italiani and Boraschi, 
2014; Tarique et al., 2015). M1 macrophages present during acute periods of 
infection/injury and produce cytokines such as TNFa, inducible nitric oxide synthase 
(iNOS) and IL-6 to induce inflammation (Olingy et al., 2017). M2 macrophages are seen 
at latter stages and encourage arteriogenesis via production of interleukin-10 (IL-10) and 
vascular endothelial growth factor (VEGF) (Olingy et al., 2017). NO produced by M1 
macrophages acts as an effector for microbicidal activity, whilst ornithine, produced by 
M2 macrophages stimulates fibrosis, collagen and polyamine synthesis for cell 
proliferation and repair (Italiani and Boraschi, 2014). The M1 and M2 monocytic 
subtypes can be identified by the following protein expression profiles in human blood; 
CD14hiCD16- and CD14+CD16+, respectively (Olingy et al., 2017). Metabolism affects the 
phenotype of macrophages, M1 macrophages are glycolytic but M2 macrophages 
oxidise fatty acids (Varela et al., 2018).  
Most antigen encounters occur in the human intestine. In the intestinal mucosa, 
macrophages are amongst the most abundant leukocytes and are crucial for 
homeostasis (Bain and Mowat, 2014). Intestinal macrophages express cluster of 
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differentiation 11c (CD11c) along with major histocompatibility complex class II (MHC-
II) (Bain and Mowat, 2014). Unlike macrophages present elsewhere, contact to stimuli 
such as ingested bacteria, does not cause pro-inflammatory reactions by mucosal 
macrophages. They also lack the ability of nitric oxide generation and respiratory burst 
(Bain and Mowat, 2014).  
 
 Phagocytosis 
Phagocytosis (Figure 3) is the recognition and cellular uptake of particles larger than 0.5 
µm by phagocytes, into a phagosome using a process called endocytosis (Gordon, 2016; 
Fang et al., 2017). Pathogen recognition causes extension of pseudopodia which 
surrounds the particle (Richards and Endres, 2014). Following internalisation, the 
phagosome maturates, by fusing with lysosomes to produce a phagolysosome: a 
microbicidal vacuole (Rosales and Uribe-Querol, 2017). Particles are destroyed via 
secretion of lysozyme and proteases from the phagolysosome and generation of toxic 
reactive oxygen compounds by the nicotinamide adenine dinucleotide phosphate 
(NADPH) oxidase complex (Merle et al., 2015). 
This process is important for pathogen ingestion but also for homeostasis and clearance 
of apoptotic cells (Rosales and Uribe-Querol, 2017). Monocytes, macrophages, dendritic 
cells and neutrophils are very efficient at phagocytosis and are described as professional 
phagocytes (Arandjelovic and Ravichandran, 2015). Non-professional phagocytes 
include epithelial and endothelial cells that are unable to engulf microorganisms but can 
eliminate apoptotic cells (Rosales and Uribe-Querol, 2017).  
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Figure 3: The Phagocytic Pathway (Gordon, 2016). A diagram showing the process of phagocytosis; internalisation 
into the early phagosome, which matures into a phagolysosome with help of the Golgi apparatus and fusion with 
lysosomes. pH of the phagolysosome lowers to acidic conditions for microbicidal activity. 
 
Receptors involved in phagocytosis can be opsonic or non-opsonic. Opsonic receptors 
recognise opsonins such as complement, antibodies and mannose-binding lectin from 
the host, which bind and target microorganisms (Rosales and Uribe-Querol, 2017). 
These opsonic receptors include, the fragment crystallisable (Fc) and complement 
receptors (Rosales and Uribe-Querol, 2017). Non-opsonic receptors include CD33, 
Dectin-1 and scavenger receptors; these recognise microorganisms directly (Rosales and 
Uribe-Querol, 2017).  
TLRs are sensors, they do not enable phagocytic entry, but instead they stimulate uptake 
and signalling by cooperating with other non-opsonic receptors (Gordon, 2016). 
Opsonization by C3 fragments initiates different cellular processes compared to 
immunoglobulin type G (IgG) opsonization (Merle et al., 2015). Activation by 
complement receptor 3 (CR3) causes a slower reaction involving guanosine 
triphosphatase (GTPase) Rho dependant actin polymerization, whilst Fcg receptor 
activation results in quicker engulfment via GTPase Rac and cell division control protein 
42 (Cdc42) mediated membrane extensions (Merle et al., 2015). 
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1.4 Arabinoxylan (AX) 
Arabinoxylan (AX) is a hetro-polysaccharide, composed of b-(1-4)-linked D-
xylopyranosyl residues connected to a-L-arabinofuranose side chains (Hald et al., 2016; 
Fadel et al., 2017). The arabinose functional groups are often linked to the C(O)-2 and/or 
C(O)-3 positions of the xylose units, depending on the source of AX (Sahasrabudhe et 
al., 2016). The C(O)-5 position of arabinose may also consist of ester linked phenolic 
acids (Mendis et al., 2017). 
Dietary AX is primarily found in cereal grains including corn, wheat and rice bran, and is 
a major component in whole grain dietary fibres (Lattimer and Haub, 2010; 
Sahasrabudhe et al., 2016). The abundance of AX in these food groups, which constitutes 
a large proportion of the human diet, suggests that AX is introduced in large quantities 
to the GI tract (Mendis et al., 2016). AX is quickly fermented by colon microflora, much 
like soluble fibres, in the GI tract (Lattimer and Haub, 2010).  
AX exerts immunomodulatory properties such as phagocytosis augmentation and anti-
tumour activities in mice (Zhou et al., 2010; Cao et al., 2011). 
Xylose is metabolised in the pentose phosphate pathway, via two main routes of entry; 
the xylose isomerase pathway and the redox pathway, common amongst bacteria and 
eukaryotes respectively (Mendis et al., 2016). 
The similarities between lipopolysaccharide (LPS) and AX from rice bran and corn husk, 
in terms of molecular structure suggests that TLR-4 might be a possible receptor for AX 
(Zhang et al., 2015).  
 
1.5 MGN-3/Biobran 
MGN-3/Biobran, hereby referred to as MGN-3, is an enzymatically modified 
arabinoxylan extracted from rice bran (Ghoneum and Jewett, 2000; Ooi et al., 2017). 
Rice bran is acquired from milling rice, and is a source of dietary fibre, vitamins, proteins 
and lipids, with links to numerous health benefits (Ghoneum and Agrawal, 2011). 
Shitake mushroom (Lentinus edodes mycelia) derived carbohydrate hydrolysing 
enzymes are used for MGN-3 modification (Perez-Martinez et al., 2015). AX is the major 
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chemical structure of MGN-3, consisting of a xylose and an arabinose polymer in the 
main and side chain respectively (Noaman et al., 2008). 
The safety of MGN-3 has been confirmed and is stated as a non-toxic agent. It presented 
negative for mutagenicity in the Ames test, genotoxic, antigenicity and subchronic 
toxicity testing in guinea pig and rat models have also established the non-toxic state of 
MGN-3 (Ghoneum and Gollapudi, 2011). It has been shown that >36g/kg is classed as 
the lethal dose 50% (LD50) for MGN-3 (Ghoneum and Gollapudi, 2011). 
 
 MGN-3 and immunomodulation 
MGN-3 is a potent biological response modifier (BRM), which can enhance host immune 
system function by augmentation of macrophage, NK, T and B cell function and 
interferon-gamma (IFN-g) and TNF-a production (Gollapudi and Ghoneum, 2008). 
Anticancer properties of MGN-3 include: in vivo cancer cell apoptosis stimulation, 
tumour growth inhibition in mice and human breast cancer sensitisation to 
chemotherapy agents (Badr El-Din et al., 2008; Noaman et al., 2008; Ghoneum et al., 
2014). MGN-3 with conventional cancer treatment, has been shown to have synergistic 
anti-tumour properties against certain cancers, for example hepatocellular carcinoma 
and breast cancer (Perez-Martinez et al., 2015). In addition to interventional cancer 
therapies, MGN-3 has been described to improve overall survival of hepatocellular 
carcinoma adult patients in a clinical trial (Bang et al., 2010). A study by Ghoneum and 
Gollapudi showed enhancement of yeast-induced apoptosis of breast cancer (MCF-7) 
cells, whilst an earlier study indicated MGN-3 induced sensitisation to apoptosis by 
decreasing B-cell lymphoma 2 (Bcl-2) expression in human leukemic cells (Ghoneum and 
Gollapudi, 2003; Ghoneum and Gollapudi, 2005). 
Induction of NK cell cytotoxicity against adult tumour cells both in vitro and in vivo can 
also be achieved (Ghoneum and Gollapudi, 2011; Perez-Martinez et al., 2015). Paediatric 
tumour cell lines have also been tested; an improvement in NK cytotoxicity in vivo and 
in vitro was also observed upon MGN-3 stimulation (Perez-Martinez et al., 2015). MGN-
3 can enhance maturation and activate human dendritic cells in vitro for cytokine 
production (Cholujova et al., 2009; Ghoneum and Agrawal, 2011). Dendritic cells, 
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activated by MGN-3 can prime CD8+ cells to express higher levels of granzyme B, 
encourage CD4+ T cell proliferation and cytokine production (IL-10, 17 and IFN-g) 
(Ghoneum and Agrawal, 2014). 
High doses of MGN-3 resulted in M0 to M1 macrophage modification, which released 
pro-inflammatory cytokines, TNFa, IL-6 and IL-8 (Perez-Martinez et al., 2015). 
MGN-3 mediated increase of TNFa production in peripheral blood lymphocytes is dose 
dependant, the increase being higher at the concentration of 1 mg/ml compared to 0.1 
mg/ml (Ghoneum and Jewett, 2000). In peripheral blood lymphocytes, MGN-3 caused 
increased CD69 expression and also IFN-g; however this was at lower levels in 
comparison to TNFa (Ghoneum and Jewett, 2000). 
Discovery of radio-resistance properties have suggested potential uses for MGN-3 
(Ghoneum et al., 2013). An in vivo mice study found that MGN-3 treatment provided 
protection to the parameters of the complete blood count, complete bone marrow 
cellularity and weight of the spleen, against irradiation-induced damage (Ghoneum et 
al., 2013). MGN-3 can also enhance antioxidant scavenging enzyme activity along with 
free radical reduction in tumour bearing mice with antioxidant disturbances (Noaman 
et al., 2008; Ghoneum et al., 2013).  
Another in vivo study involving mice with Ehrlich carcinoma showed tumour inhibitory 
activity by MGN-3 (Ghoneum and Agrawal, 2011). These anti-cancer properties were 
associated to the T and NK cell activation and T regulatory lymphocyte generation 
abilities in patients with metastatic or locally restricted tumours (Lissoni et al., 2008).  
The safety of MGN-3 was confirmed upon human investigation in clinical trials on cancer 
patients and analysis of blood chemistry (Ghoneum and Matsuura, 2004; Ghoneum et 
al., 2013). 
A recent study demonstrated that one month of daily MGN-3 supplementation (500 
mg/day) increased the activity of NK cells in the geriatric population, in a randomised, 
double-blind, placebo controlled human trial (Elsaid et al., 2018). The mechanism of 
action is currently unknown; however, it is suggested that MGN-3 may activate protein 
kinase C via stimulation of early signalling events or cause an increase of NK granzyme 
B and granular perforin levels (Elsaid et al., 2018). 
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 Beta-glucan (b-glucan) 
b-glucan is a natural polysaccharide and functional food ingredient, which is present in 
MGN-3 (Ghoneum et al., 2013; Stier et al., 2014). It is a carbohydrate linked with glucose 
molecules which is present in the cell walls of fungi and yeast, as a main structural 
component (Volman et al., 2008).  
The macromolecular structure of b-glucan differs depending on the source (Volman et 
al., 2008). In oat and barley, b-glucans are unbranched with 1,3 and 1,4 b-linked 
glycopyranosyl residues, whereas the unbranched b-glucan from bacterial cell walls 
consists of only 1,3 b-linked glycopyranosyl residues (Volman et al., 2008).  
b-glucan has been shown to express antioxidant properties, anticancer activity and 
modulate immune responses (Ghoneum et al., 2013; Byun et al., 2016). Human 
peripheral blood mononuclear cell proliferation can be induced by b-glucan, along with 
monocyte derived dendritic cell maturation (Chan et al., 2009). Short chain fatty acid 
production from b-glucan is suggested to be a plausible mechanism for its metabolic 
effects (Lattimer and Haub, 2010). 
 
1.6 Cell surface receptors 
Dietary fibre is recognised by PRRs such as TLRs and C type lectin receptors such as 
Dectin-1 (Sahasrabudhe et al., 2016). Receptors allow the cells to interact with the 
external environment for nutrient transport and signal transduction (Shankaran et al., 
2007). Physical properties of ligands affect receptor behaviour such as binding specificity 
(Shankaran et al., 2007). 
 
 Toll-like receptors (TLRs) 
TLRs are PRRs which are required for immuno-regulation and mediation of inflammatory 
cytokine production, found on the surface of monocytes, macrophages and dendritic 
cells (Fang et al., 2017). TLRs found in humans comprise TLR1 – 10, some of which are 
located on the cell surface whilst others are intracellular (Kawasaki and Kawai, 2014). 
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Bacterial and viral agents are recognised by TLRs, these include nucleic acids, proteins 
and lipids (Sahasrabudhe et al., 2016). Many bacterial lipopolysaccharides are 
recognised by TLRs, leading to activation of signalling pathways involved in endocytosis 
(Mendis et al., 2016; Fang et al., 2017). TLR-2 can be activated by inulin-type fructan to 
prevent pathogen entry via intestinal barrier enhancement (Sahasrabudhe et al., 2016). 
The structure of TLR-4 is comprised of a toll/interleukin-1 receptor (TIR) domain linked 
to an extracellular domain composed of leucine-rich repeats (Kuzmich et al., 2017). TLR 
signalling can coordinate both the innate and adaptive immunity through the 
stimulation of cytokine and chemokine expression (Plato et al., 2013). Two signalling 
pathways can be activated by TLRs after engagement, including the MyD88-dependant 
pathway and the TIR domain-containing adaptor inducing interferon-beta (TRIF)-
dependant pathway (Kawasaki and Kawai, 2014). Both pathways lead to the activation 
of mitogen-activated protein kinases (MAPKs) and NF-kB (Kawasaki and Kawai, 2014). 
 
 Dectin-1 receptor 
b-glucan is proven to bind to the Dectin-1, a type II transmembrane protein receptor 
that binds and recognises the b-1-3 and 1-6 linkages (Chan et al., 2009; Sahasrabudhe 
et al., 2016). These specific PAMPs activate NF-kB and are expressed by Aspergillus 
fumigatus and Candida albicans for example (Geijtenbeek and Gringhuis, 2009). Dectin-
1A and Dectin-1B are correspondingly, the full length and stalk-less variants of the 
Dectin-1 receptor. Not only is Dectin-1 activated by b-glucan but by AX also 
(Sahasrabudhe et al., 2016). 
Dectin-1, when activated can mediate phagocytic pathogen detection, phagocytosis and 
cytokine production (Chan et al., 2009; Gordon, 2016). This receptor is expressed on 
innate immune cells such as macrophages, DCs and neutrophils (Chan et al., 2009).  
  
1.7 Lipopolysaccharide (LPS) 
Lipopolysaccharide (LPS) is a powerful inducer of inflammation, found in the outer 
membrane of gram-negative bacteria such as Escherichia coli (E. coli) (Zhang et al., 2013; 
de Lima et al., 2014). There are three  components that make up LPS; the O-antigen 
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polysaccharide, lipid A and core oligosaccharide (Shimada et al., 2012). Immune cells, 
especially macrophages are stimulated by the lipid A fraction of LPS (Shimada et al., 
2012).  
LPS is recognised by TLR-4, which leads to pro-inflammatory cytokine production (de 
Lima et al., 2014). LPS interaction requires myeloid differentiation protein 2 (MD2) to 
associate with TLR-4 to form a heterodimer called the TLR4-MD2 complex (Choi et al., 
2009). TLR4-MD2-LPS complex formation stimulates myeloid differentiation factor 88 
(MyD88) to initiate pro-inflammation signalling (Fang et al., 2017). These signalling 
cascades subsequently activate protein kinase B (PKB) and phosphatidylinositol-3-kinase 
(PI3K) (Fang et al., 2017). 
 
1.8 Methicillin resistant Staphylococcus aureus (MRSA) 
Staphylococcus aureus (S. aureus) is a non-motile, gram positive coccus with a diameter 
of around 0.6 µm and is usually found on human skin (Green et al., 2012; Vitko and 
Richardson, 2013). It is both a commensal and an opportunistic pathogenic bacterium 
(Tong et al., 2015). 
Methicillin resistant Staphylococcus aureus (MRSA), are strains of Staphylococcus that 
has established a resistance against b-lactam antibiotics, including cephalosporins and 
penicillins due to the production of b-lactamase (Lovering et al., 2012; Moellering, 2012; 
Pathare et al., 2015). MRSA was identified initially in England in 1961, a few years after 
methicillin development, and is a common cause of infection in healthcare and the 
community (Green et al., 2012; Habib et al., 2015). Almost 50% of all S. aureus infections 
is caused by MRSA (Adani et al., 2018). It can cause toxic shock syndrome, bacteraemia, 
septicaemia and surgical site infections (Vitko and Richardson, 2013).  
The prognosis of infection with MRSA is poor, especially in MRSA related bacteraemia 
with a mortality rate of 90 days (Bal et al., 2017). S. aureus is one of the leading causes 
of bacteraemia, showing elevated levels of mortality and morbidity and costs in 
association with MRSA (Adani et al., 2018). 
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 Types of MRSA 
Healthcare-associated/nosocomial MRSA are usually confined to healthcare facilities 
and results in bloodstream, respiratory and urinary tract infections (Boswihi and Udo, 
2018). The risk factors of healthcare-associated MRSA include prolonged hospitalisation, 
especially in intensive care, old age, antibiotic use and use of intramuscular devices 
(Boswihi and Udo, 2018). The rate of MRSA-related nosocomial pneumonia has seen an 
increase over the past fifty years, especially in the ageing population (Kawanami et al., 
2016). Significant mortality rates and substantial healthcare costs are associated with 
this type of infection (Shorr et al., 2010).  Treatment for MRSA infection is often 
challenging in the older population as antimicrobial therapy is typically less effective, 
and due to immunosenescence present with high mortality (Pomorska-Wesołowska et 
al., 2017).  
Community-associated MRSA is seen in individuals without a history of hospitalisation. 
These were most commonly presented as soft tissue and skin infections but post-
influenza pneumonia, necrotising fasciitis and bacteraemia are amongst some of the 
more serious infections that have been reported (Boswihi and Udo, 2018). 
 
 Treatments and limitations 
MRSA is not only resistant to methicillin but also to a large proportion of non-b-lactam 
antibiotics (Boswihi and Udo, 2018). Vancomycin was the most effective treatment for 
MRSA infections in the 1980s, until an isolate of S. aureus was discovered in 1997 with 
reduced susceptibility to this antibiotic, followed by the discovery of a resistant strain 
(Chang et al., 2003). 
Vancomycin is the standard first-line treatment for MRSA infections and can still be used 
to treat pneumonia, bacteraemia and acute skin infections. Linezolid and daptomycin 
are used to treat pneumonia and bacteraemia respectively along with skin infections 
(Bal et al., 2017; Adani et al., 2018). However, antibiotics  are related to common 
adverse effects including abdominal pain, nausea, itching and headache (Green et al., 
2012).  
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Resistance to current treatments may materialise over time, further limiting the number 
of treatments available, which highlights the importance of the discovery of new 
strategies to overcome this problem. 
 
1.9 Effect of MGN-3 on the phagocytosis of MRSA 
Antibiotic resistance is a global danger to human health, associated with high rates of 
mortality and morbidity (Frieri et al., 2016). The death rate from nosocomial infections  
caused by resistant bacteria in Europe alone is estimated at 25,000 people per year 
(MacGowan and Macnaughton, 2017). The alarming rate at which pathogens are 
becoming resistant to conventional therapies (Frieri et al., 2016) is a reason for the 
urgent need to develop new or alternative strategies to combat bacterial infections. 
Enhancing the host’s natural innate immunity to problematic pathogens, especially 
when used in conjunction with traditional antibiotic therapies, may increase the success 
rate of clearing persistent infections. Dietary fibres such as AX and b-glucan have been 
shown to stimulate innate immunity and promote phagocytosis (Cao et al., 2011; Byun 
et al., 2016). Thus, one potential strategy would be to encourage the dietary intake of 
foods containing AX or supplements such as MGN-3. This could be beneficial, especially 
for immunocompromised individuals as constant, low level immune system stimulation 
could assist in clearing potential pathogens before infection presents. Given the increase 
in the older population (>65 years) (MacGowan and Macnaughton, 2017) immune 
system enhancement could help in the reduction of hospitalisation; where patients are 
more susceptible to infection, and therefore a reduction in antibiotic use and healthcare 
costs. 
The mechanisms by which dietary fibres promote the function of phagocytes are largely 
unknown. Uncovering the mechanisms of action could lead to the production and/or 
enhancement of targeted drugs and therapies. Therefore, this study focused on the 
effect of MGN-3 on macrophage phagocytosis and potential receptors that may mediate 
bacterial clearance. Moreover, there has been little research to determine the influence 
of dietary fibres on the clearance of antibiotic-resistant strains of bacteria such as MRSA. 
MGN-3 is known to stimulate systemic immune activities (Gollapudi and Ghoneum, 
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2008), suggesting it may be of therapeutic benefit not only to clear pathogens that gain 
host entry via the gut but also bacteria that infect non-intestinal tissues such as wound 
pathogens like MRSA. Indeed, the transport of dietary fibres across the gut lining into 
non-intestinal tissues of the immune system has been recently reviewed (Mendis et al., 
2016). Rice et al. (2005) isolated fluorescently labelled β-glucan from a subpopulation 
of the intestinal epithelial cells and Peyer’s patches after oral administration, thus 
suggesting dietary fibres can be taken up from the intestinal lumen by M-cells and 
transported to underlying lymphoid tissue. Mucosal DC uptake of dietary fibres occurs 
through sampling and interacting with gut contents locally via cellular projections that 
cross the epithelium (Valzasina et al., 2001; Sandvik et al., 2007). In addition, murine 
studies have shown that orally administered dietary fibres are taken by GI macrophages 
and transported to the spleen, lymph and bone marrow (Hong et al., 2004). Thus, the 
principal mechanisms through which dietary fibre is taken up from the diet appear to be 
via by M-cell, DC and/or macrophage transportation across the mucosal epithelium. 
Once transported to the spleen, lymph tissues and bone marrow dietary fibres such a 
MGN-3 could modulate phagocyte responses in non-intestinal, peripheral tissues by 
interacting with inflammatory cells recruited from circulation, such as monocytes that 
differentiate into tissue macrophages at sites of infection (Ginhoux and Jung, 2014). 
 
1.10 Hypotheses  
Alternative hypothesis: MGN-3 significantly promotes the clearance of MRSA by U937 
macrophages.  
Null hypothesis: MGN-3 has no significant effect on the clearance of MRSA by U937 
macrophages. 
 
1.11 Aim 
To investigate the effect of MGN-3 on the clearance of MRSA by human U937 
macrophages. 
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1.12 Objectives 
The following specific objectives were formulated to achieve the aim: 
1. To generate and confirm the differentiation of U937 monocytes to CD11c+ 
macrophages. 
2. To investigate the internalisation of MGN-3 by human U937 macrophages.  
3. To investigate the effect of MGN-3 on the phagocytosis of MRSA by human U937 
macrophages.  
4. To visualise MGN-3 induced internalisation of MRSA by human U937 
macrophages. 
5. To investigate the mechanism of action by which MGN-3 promotes phagocytosis 
in U937 macrophages.  
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2. Methodology 
 
2.1 Materials 
U937 human monocyte cell line, isolated from a histiocytic lymphoma of a 37-year-old 
male (Health Protection Agency Culture Collections, Salisbury) 
MGN-3/Biobran (Revital, Middlesex) 
RPMI-1640 media with L-glutamine and 25 mM HEPES (Thermo Fisher Scientific, 
Loughborough) 
Foetal Bovine Serum (FBS) (Sigma-Aldrich, Dorset) 
Penicillin-Streptomycin (Thermo Fisher Scientific, Loughborough) 
Phorbol 12-myristate 13-acetate (PMA) (Applichem, Darmstadt) 
Lipopolysaccharide (LPS) (Sigma-Aldrich, Dorset) 
Methicillin Resistant Staphylococcus aureus (MRSA) – strain 11, a patient specimen 
collected at Withington Hospital, Manchester.  
Nutrient Broth (Oxoid, Basingstoke) 
Nutrient Agar (Oxoid, Basingstoke) 
Saline (Sigma-Aldrich, Dorset) 
Trypsin EDTA 0.25% (Thermo Fisher Scientific, Loughborough) 
0.4% Trypan blue (Sigma-Aldrich, Dorset) 
Phosphate buffered saline (PBS) (Fisher Scientific, Loughborough) 
Phloroglucinol (Sigma-Aldrich, Dorset) 
Hydrochloric acid (concentrated) (Thermo Fisher Scientific, Loughborough) 
D-(+)-Xylose (Sigma-Aldrich, Dorset) 
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Acetic acid (glacial) (Sigma-Aldrich, Dorset) 
D-(+)-Glucose (Sigma-Aldrich, Dorset) 
Ethanol (99%) (Sigma-Aldrich, Dorset) 
Whole glucan particles (WGP) soluble (Invivogen, France) 
Whole glucan particles (WGP) dispersible (Invivogen, France) 
TLR-4 inhibitor (TLR4-IN-C34) (Sigma-Aldrich, Dorset) 
Heteroxylan primary antibody (Abcam, Cambridge) 
Fluorescein isothiocyanate (FITC) Goat Anti-Rat IgM mu chain (Abcam, Cambridge) 
Normal goat serum (Vector Laboratories, Peterborough) 
Hanks balanced salt solution (HBSS) (Sigma-Aldrich, Dorset) 
Fluorescein isothiocyanate (FITC) conjugated anti-human CD11c antibody (Clone Bu15; 
BioLegend, UK) 
Glutaraldehyde (Sigma-Aldrich, Dorset) 
Paraformaldehyde (Sigma-Aldrich, Dorset) 
Silicon wafers (Sigma-Aldrich, Dorset) 
TritonX-100 (Sigma-Aldrich, Dorset) 
Nutrient agar (Thermo Fisher Scientific, Loughborough) 
Nutrient broth (Thermo Fisher Scientific, Loughborough) 
 
2.2 Ethics 
The ethical application (SE171862; Appendix 1) for this project was approved by the 
Manchester Metropolitan University ethics committee on 23/04/18. 
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2.3 Media and solutions 
Complete medium (CM) – RPMI-1640 1X medium (with L-Glutamine and 25 mM HEPES), 
supplemented with 10% FBS and 2% penicillin-streptomycin. 
Antibiotic-free medium – RPMI-1640 1X medium (with L-Glutamine and 25 mM HEPES), 
supplemented with 10% FBS. 
Colourless RPMI medium – RPMI-1640 1X medium (without phenol red), supplemented 
with 10% FBS. 
MGN-3 solution – MGN-3 was dissolved in antibiotic-free medium, using heat and 
sonication to ensure the sample was fully dissolved. The sample was filtered using a 0.2 
µm sterile filter before dilution to the following concentrations – 0.5, 1 and 2 mg/ml. 
The solutions were stored at 4°C but heated up to 37°C prior to cell culture use. 
LPS – LPS (from E.coli) was diluted in antibiotic-free medium to make up concentrations 
of 1 and 5 µg/ml. The samples filtered using a 0.2 µm sterile filter and stored at 4°C but 
heated up to 37°C prior to cell culture use. 
TLR-4 inhibitor – A stock solution was prepared in HBSS. The stock solution was diluted 
in antibiotic-free medium to form a concentration of 250 ng/ml. The samples were put 
through a 0.2 µm sterile filter and stored at 4°C but heated up to 37°C prior to cell 
culture use. 
WGP soluble (Dectin-1 receptor inhibitor) – A stock solution was prepared in PBS at a 
concentration of 1 mg/ml before further dilution in PBS at 100 µg/ml. Antibiotic-free 
medium was used to further dilute the solution for cell culture use at 2 and 10 µg/ml. 
The samples were sterile filtered (0.2 µm) and stored at 4°C but heated up to 37°C prior 
to cell culture use. 
WGP dispersible (Dectin-1 receptor activator) – A stock solution at 1 mg/ml was 
prepared in antibiotic-free medium. A further dilution in antibiotic-free medium was 
carried out to give a concentration of 200 µg/ml. The samples were sterile filtered (0.2 
µm) and stored at 4°C but heated up to 37°C prior to cell culture use. 
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2.4 Cell culture 
U937 monocytes were cultured in CM and incubated at 37°C with 5% CO2. The cells were 
re-suspended in fresh CM every two days and set at 0.5 x 106 viable cells/ml for routine 
growth. For experimental purposes, the cells were cultured at 1 x 106 viable cells/ml. 
The cells were centrifuged at 1000 RPM for 7 minutes to collect cell pellet before re-
suspension. 
 
 U937 monocyte differentiation into macrophage-like cells 
U937 monocytes, set at a concentration of 1 x 106 cells/ml, were differentiated into 
adherent macrophage-like cells with the addition of Phorbol 12-myristate 13-acetate 
(PMA) at 50 ng/ml, followed by a 72-hour incubation at 37°C and 5% CO2 (Sproston et 
al., 2018). 
PMA is a phorbol ester used to promote monocyte/macrophage differentiation, via 
protein kinase C activation to alter gene expression as described previously (Song et al., 
2015). 
Cell viability was maintained above 80% during culture. Cell growth and viability were 
evaluated using a Biorad TC10 automated cell counter and trypan blue (0.4% in PBS) cell 
staining. A volume of cell suspension was mixed with an equal amount of trypan blue 
dye. The negative charge of trypan blue results in non-interaction with intact cell 
membranes, therefore, the cells that stain are considered non-viable (Tran et al., 2011). 
 
2.5 Flow cytometry – CD11c analysis 
The cells were cultured and differentiated as described in section 2.4.  
Once differentiated, the cells were detached from plate wells using 40 µl trypsin EDTA 
for 5 minutes followed by 40 µl antibiotic-free medium for neutralisation. The cells were 
then centrifuged for 5 minutes at 500g before resuspending the pellet in 500 µl CM. The 
cells were then centrifuged at 500g for 5 minutes before washing twice with PBS. 
Subsequently, the cells were fixed in 4% paraformaldehyde at room temperature for 10 
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– 15 minutes. Following incubation, cells were centrifuged immediately for 5 minutes at 
500g and washed twice in PBS, discarding supernatant. FITC conjugated anti-human 
CD11c antibody was prepared at a 1:50 concentration, using wash buffer (10% FBS in 
PBS) as a diluent. The antibody was added to the cell pellet and incubated for 30 minutes 
at room temperature. The cells were washed twice in PBS before resuspension in 500 µl 
PBS for analysis.  
The expression of CD11c (cell surface marker) was assessed on 10,000 live, individual 
cells with a BD Accuri C6F1 Cytometer using BD Accuri C6 software. The data was 
analysed after gating events in the forward scattered light (FSC)/side scattered light 
(SSC) and fluorescence parameter 1 (FL1-A). Data was displayed as the median 
fluorescent intensity (MFI) relative to unstained monocytes (negative control). 
 
2.6 MGN-3 internalisation 
U937 monocytes were cultured in CM and set at a concentration of 1 x 106 cells/ml as 
stated in section 2.4. The cells were differentiated in the presence of PMA (100 ng/ml) 
in T75 cell culture flasks for 24 hours at 37°C with 5% CO2. The culture medium was 
changed after 24 hours and incubated in the same conditions for a further 48 hours.  
The adherent macrophage-like cells were treated with MGN-3 at 2 mg/ml, LPS at 5 
µg/ml and CM as a control for 24 hours at 37°C with 5% CO2.  
The cells were washed four times following treatment incubation using colourless RPMI 
medium. All washes were stored for analysis. Trypsin EDTA was used to lift adherent 
cells before analysing cell counts and viability as described in section 2.4.1.  
The cells were then centrifuged at 1000 RPM for 7 minutes. The supernatant was 
discarded, and the cells were resuspended in PBS, followed by centrifugation at 1000 
RPM for 7 minutes. The supernatant was discarded, and the cells were resuspended in 
0.5 ml sterile water, ready for analysis. 
MGN-3 solution in CM at concentrations of 0.2, 2 and 4 mg/ml and CM alone were 
prepared for analysis, in order to determine the amount of xylose actually added to the 
cells and any CM interference. 
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 Pentosan determination 
Extracting solution was prepared by mixing 110 ml acetic acid (glacial), 2 ml hydrochloric 
acid (concentrated), 5 ml phloroglucinol (20% w/v in ethanol) and 1 ml glucose solution 
(1.75% in distilled water). 
1 ml of sample containing cells was mixed with 5 ml extracting solution in glass test tubes 
before placing in a vigorously boiling water bath for 25 minutes to observe for a change 
in colour (dependant on pentosan concentration). Afterwards, the samples were rapidly 
cooled on ice for analysis.  
The samples were analysed on a spectrophotometer. The absorbance (A) was read at 
552 nm (A552nm) and corrected by subtracting the absorbance at 510nm (A510nm) for each 
sample. 
 
 Standard calibration curve 
A standard calibration curve was created using samples prepared following section 
2.6.1. D-(+)-Xylose was dissolved in distilled water at a concentration of 2 mg/ml. 
Standards were prepared at the following concentrations: 0, 0.01, 0.02, 0.05, 0.1, 0.2, 
0.5, 1 and 1.5 mg/ml. 
The calibration curve was plotted based on the corrected absorbance (A552nm – A510nm) 
from the spectrophotometer readings of the standards as described in section 1.6.1. The 
amount of xylose in each sample was then determined by interpolation from the 
standard calibration curve. 
 
2.7 Confocal microscopy 
U937 monocytes were seeded onto sterile silicon wafers (1 cm2) in a 24-well cell culture 
plate for differentiation into macrophage-like cells (see section 2.4.1). Treatments 
include an untreated negative control, MGN-3 at 2 mg/ml and LPS at 5 µg/ml. The cells 
were incubated with the treatments for 24-hours in 37°C with 5% CO2. 
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The silicon wafers were washed in PBS after removal of the supernatant from the wells. 
The wafers were then fixed with 4% paraformaldehyde for 10 – 15 minutes. The samples 
were washed using PBS three times to remove remaining paraformaldehyde, then 
permeabilised with 1% TritonX-100 in PBS for 5 – 8 minutes, followed by repeat washes 
with PBS. The samples were then blocked using blocking buffer (5% goat serum in 0.1% 
TritonX-100 in PBS) for one hour. After blocking, the samples were immediately treated 
with heteroxylan primary antibody at a 1:100 concentration and incubated at 4°C for 24 
hours. After several washes with PBS, FITC goat anti-Rat IgM mu chain (secondary 
antibody) at a 1:50 concentration was incubated with the samples for one hour at room 
temperature in the dark. Samples were then mounted for visualisation. These antibody 
concentrations were confirmed as optimal for the detection of MGN-3 fluorescence 
when the concentrations were experimentally varied. 
U937 macrophages were treated with 2.0 mg/ml MGN-3 and 5.0 µg/ml LPS. Untreated 
macrophage controls were also prepared along with negative controls for the primary 
and secondary antibody to confirm effectiveness of the assay. The primary antibody 
negative control was absent of macrophages, but the silicon wafer was treated with 
MGN-3 2.0 mg/ml. The cells in the secondary antibody negative control was also treated 
with 2.0 mg/ml MGN-3, however, the primary antibody was exchanged for the blocking 
buffer in the staining process. 
The samples were analysed and captured on a Carl Zeiss, AX10 Imager Z1 fluorescence 
microscope using AxioVision 4.8 software. Images were captured at 20x and 63x 
magnifications. 
 
2.8 Host-pathogen interaction assay 
 MGN-3/LPS treatment 
U937 macrophages were treated with solubilized MGN-3 solution at concentrations of 
0.5, 1 and 2 mg/ml and LPS at concentrations of 1 and 5 µg/ml. The negative and positive 
controls were performed, consisting of macrophages and bacteria (no treatment) and 
bacteria alone in the absence of macrophages respectively. Treatments and the controls 
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were incubated for 24-hours at 37°C and 5% CO2. A duplicate plate was prepared to 
assess cell counts and viability. 
Antibiotic-free medium was used from this stage onwards to ensure unaffected 
bacterial growth.  
 
 Cell counts and viability 
Macrophage counts obtained from the replica plate. Adhered cells were detached from 
the well plates using 40 µl trypsin EDTA for 5 minutes followed by 40 µl antibiotic-free 
medium for neutralisation. Cell counts and viability were measured using 0.4% trypan 
blue and a Biorad TC10 automated cell counter, as described in section 2.4.1. 
 
 Bacterial preparation 
MRSA, strain 11, was cultured onto nutrient agar plates from a frozen stock, under 
aseptic conditions using the streak plating method. This was incubated for 24 hours at 
37°C to allow for bacterial growth. One to two separate MRSA colonies from the streak 
plate were cultured in nutrient broth for 24-hours at 37°C. Serial dilutions of the broth 
using saline was carried out under aseptic conditions to achieve an optimal 
concentration of 2 x 104 CFU/ml.  
 
 Host Pathogen Interaction Assay 
MRSA at 1 x 104 CFU/ml was added to each well containing U937 macrophages, followed 
by a 3-hour incubation at 37°C and 5% CO2 to enable phagocytosis to take place. 
The supernatant (100 µl) from the well plate were collected into separate bijoux, in 
addition to 450 µl of trypsin and 450 µl of antibiotic-free medium. 100 µl of this solution 
was cultured onto nutrient agar plates, followed by a period of incubation at 37°C for 
24 hours. Bacterial colony recovery was collected after this period for quantification. 
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2.9 Host-pathogen interaction with receptor competition 
U937 macrophages were treated, following the protocol in section 2.8. The treatments 
used were as follows; LPS at 10 µg/ml together with MGN-3 at concentrations of 1, 2 
and 4 mg/ml. The treated cells were subsequently incubated for 24 hours at 37°C and 
5% CO2. 
 
2.10 Host-pathogen interaction with Toll-like receptor 4 (TLR-4) inhibitor 
Using the protocol in section 2.8, TLR-4 inhibitor (125 ng/ml) was added to the cells in 
conjunction with the following treatments: MGN-3 (0.5, 1 and 2 mg/ml), LPS (1 and 5 
µg/ml) and antibiotic-free medium (untreated control). The same treatments were 
replicated in the absence of TLR-4 inhibitor.  
 
2.11 Host-pathogen interaction with Dectin-1 inhibitor 
Protocol as followed in section 2.8. The controls included a negative control treated with 
antibiotic-free medium, MGN-3 at concentrations of 0.5, 1 and 2 mg/ml, LPS at 1 and 5 
µg/ml and WGP dispersible (WGPD) at 500 µg/ml. 
The inhibitor treated cells were incubated at 37°C for 1 hour with WGP soluble (WGPS) 
at 5 µg/ml, prior to activation with the above treatments for a further 24 hours. 
 
2.12 Scanning electron microscopy (SEM) 
Silicon wafers (1 cm2) were sterilised with 70% ethanol for 30 minutes before washing 
twice in PBS. Ethanol was washed off thoroughly to avoid adverse effects on the cells. 
The wafers were air dried in sterile conditions before being placed into a 24 well plate 
with sterile forceps.  
 
U937 monocytes were differentiated and set at 1 x 106 CFU/ml on the silicon wafers (see 
section 2.4.1). MRSA strain 11 at various concentrations, 1 x 104 CFU/ml, 1 x 105 CFU/ml 
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and 1 x 106 CFU/ml were seeded onto the wafers and incubated for 3 hours at 37°C with 
5% CO2 to allow for host-pathogen interaction.  
Subsequently, the samples were placed in 2.5 – 4% glutaraldehyde for 24 hours at 4°C 
to fix the samples. Glutaraldehyde was washed off the samples using firstly PBS, then 
increasing concentrations of ethanol at 20%, 40%, 60%, 80% and 100% for 15 – 30 
minutes each. Samples were then left to dry in a vacuum-assisted desiccator for 24 
hours.   
Samples were coated in gold (Au) metal using a Polaron SEM Coating System after 
mounting samples onto aluminium pin stubs. The cells were analysed using a Carl Zeiss, 
Supra 40VP machine with SmartSEM software. Images were obtained using the 
secondary electron detector, using a working distance of approximately 6 mm and an 
acceleration voltage of 2kV. 10,000x and 25,000x magnifications were used for image 
capture. 
 
2.13 Statistical analysis 
IBM SPSS Statistics (version 24) was used to perform Statistical data analysis. 
Significance differences between groups of data was determined using one-way analysis 
of variance (ANOVA), followed by a Tukey HSD post hoc pairwise comparison tests. 
Results were considered to be significant if the probability (P) = < 0.05. 
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3. Results  
 
3.1 Flow cytometry - CD11c analysis 
The CD11c cell surface marker (Figure 4, 5) was used to confirm differentiation of PMA-
treated U937 monocytes into macrophage-like cells.  Unstained monocytes were used 
as a negative control for comparison. 
 
Figure 4: CD11c analysis of U937 monocytes and macrophages using flow cytometry. Error bars represent the standard 
error of the mean (SEM).  * indicates significant difference in relative MFI (P<0.05). n = 3 in all groups. 
 
There was significantly (P<0.05) higher expression of CD11c (relative MFI) in 
macrophages stained for CD11c (mean MIF = 4.2, 98.4% CD11c+) in comparison to U937 
monocytes (mean MIF = 1.2, 1.2% CD11c+). The expression of CD11c in the unstained 
monocytes/macrophages (0.2% and 0.3%, respectively) was negligible (Figure 5). This 
upregulation of the CD11c marker confirmed the differentiation of U937 monocytes to 
macrophage-like cells following PMA treatment.  
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Figure 5: CD11c analysis of U937 monocytes and macrophages using flow cytometry. Graphs showing percentage of 
CD11c expression across all samples. 
 
 
3.2 Internalisation of MGN-3  
MGN-3 internalisation was measured by two different methods, the phloroglucinol 
colorimetric assay and confocal microscopy. 
 
 Phloroglucinol colorimetric assay to measure uptake of MGN-3 by U937 
macrophages 
Xylose concentration was measured at 0.002 mg/ml per million cells inside MGN-3 
treated macrophages. In contrast, xylose was undetected inside LPS treated 
macrophages and the negative control. The percentage uptake of the total available 
xylose/MGN-3 by U937 macrophages was estimated to be 29%. 
  
Unstained Monocytes CD11c + Monocytes 
Unstained Macrophages CD11c + Macrophages 
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 Confocal microscopy to visualise the uptake of MGN-3 & LPS by U937 
macrophages. 
Untreated (negative control) U937 macrophages (Figure 6; Panels 1A and 1B) showed 
negligible fluorescence of internalised AX. Similarly, no fluorescent signal was detected 
in MGN-3 treated macrophage in the absence of primary and secondary antibody, 
confirming neither the FITC-labelled AX primary antibody nor the secondary antibody 
were binding in a non-specific manner.  
 
  
  
  
Figure 6: Detection of AX internalisation by fluorescence microscopy was negligible in untreated (negative control) 
U937 macrophages (Panels 1A and 1B). However, there was substantial detection of AX in MGN-3 treated 
macrophages in the presence of the AX-specific primary antibody and the appropriate secondary antibody (Panels 2A 
and 2B). In contrast, fluorescence was low in LPS-treated macrophages (Panels 3A and 3B), confirming the primary 
antibody was not binding to non-specific polysaccharides. Images were captured at magnifications of 20x (A) and 63x 
(B), with scale bars of 20 and 10 µm respectively. Red arrow shows a single macrophage and green fluorescence 
indicates localisation of macrophage. 
1A 1B 
2A 2B 
3A 3B 
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U937 macrophages treated with 2.0 mg/ml MGN-3 (Figure 6: Panels 2A and 2B) showed 
substantial uptake of AX with substantial green fluorescence compared to the untreated 
negative control cells. U937 macrophages treated with LPS (Figure 6: Panels 3A and 3B) 
showed small amounts fluorescence. 
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3.3 Effect of MGN-3 and LPS on phagocytosis of MRSA 
Cultured U937 macrophages were treated with MGN-3 (0.5, 1.0 and 2.0 mg/ml) and/or 
LPS (5.0 µg/ml) alone or in combination (Figure 7). A one-way ANOVA confirmed 
statistical differences P<0.001 between treatment groups. 
 
Figure 7: Mean MRSA recovery per million viable macrophages following treatment with MGN-3 and/or LPS. Error 
bars represent the standard error mean (SEM). * represents significant differences compared to the NEG control 
(P<0.001). n = 24 for all treatments. 
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The phagocytic ability of U937 macrophages were significantly (*, P<0.001) enhanced 
by treatment with all concentrations (0.5, 1.0 and 2.0 mg/ml) of MGN-3 (MRSA recovery 
= 316, 240 and 185 CFU/ml, respectively) and even more so by 5 µg/ml LPS (MRSA 
recovery = 42 CFU/ml) compared to the negative control (MRSA recovery = 576 CFU/ml). 
Moreover, MGN-3 treatment increased phagocytosis in a dose dependant manner. 
The combination of MGN-3 and LPS resulted in an intermediate phagocytic ability 
compared to MGN-3 or LPS treatment alone. For example, 0.5 mg/ml MGN-3 combined 
with 5.0 µg/ml LPS resulted in a mean MRSA recovery of 210 CFU/ml. Similarly, MGN-3 
at 1.0 and 2.0 mg/ml showed a bacterial count of 114 and 61 CFU/ml respectively in the 
presence of LPS.  The combined MGN-3/LPS treatments significantly (P<0.001) increased 
phagocytosis compared to MGN-3 alone (at the same concentration) or the negative 
control, although not as effectively as LPS 5.0 µg/ml alone. 
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3.4 Effect of toll like receptor 4 (TLR-4) inhibition on MGN-3/LPS-mediated 
phagocytosis of MRSA 
Cultured U937 macrophages were treated with MGN-3 or LPS (as the positive control) 
in the presence/absence of the TL4-inhibitor, TLR4-IN-C34 (Figure 8).  A one-way ANOVA 
confirmed statistical differences P<0.001 between treatment groups. 
 
Figure 8: Mean MRSA recovery per million viable U937 macrophages following treatment with MGN-3 or LPS in the 
absence/presence of TLR-4 inhibitor. Error bars represent the standard error mean (SEM). * represents a significant 
difference compared to the NEG control (P<0.001). n = 24 for all treatments. 
 
As reported in section 3.3, treatment of U937 macrophages with MGN-3 resulted in 
significantly (P<0.001) increased levels of phagocytosis when compared to the negative 
control (untreated macrophages). The level of phagocytosis increased in a dose 
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dependant manner, with MGN-3 2.0 mg/ml inducing the most phagocytosis compared 
to the negative control. Treatment of U937 macrophages with LPS was more effective 
at inducing phagocytosis than the MGN-3 treatments at 0.5 and 1.0 mg/ml (P<0.001), 
with phagocytosis increasing in a dose dependant manner compared to the negative 
control (P<0.001). 
The addition of the TLR-4 inhibitor (TLR4-IN-C34) significantly (P<0.001) inhibited the 
clearance of MRSA induced by MGN-3 or LPS treatments. The mean MRSA recovery per 
million viable macrophages for 0.5, 1.0 and 2.0 mg/ml MGN-3 increased from 312, 233 
and 154 CFU/ml in the absence of TLR-4 inhibitor to 558, 543 and 517 CFU/ml in the 
presence of TLR-4 inhibitor respectively.  Similarly, mean MRSA recovery per million 
viable macrophages for 1.0 and 5.0 µg/ml LPS increased substantially from 92 and 41 
CFU/ml in the absence of TRL-4 inhibitor to 478 and 430 CFU/ml in the presence of TLR-
4 inhibitor respectively.  
No significant difference (P=1.000) was found between treatment of U937 macrophages 
with the TLR-4 inhibitor alone and the negative control, confirming the TLR-4 inhibitor 
had no inherent/direct effect on phagocytosis in the absence of appropriate receptor 
activators such as LPS (which is not a component of MRSA). 
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3.5 Effect of dectin-1 inhibition on MGN-3/LPS-mediated phagocytosis of 
MRSA 
Cultured U937 macrophages were treated with MGN-3 or LPS (as the positive control) 
in the presence/absence of the dectin-1 inhibitor, WGPS (Figure 9). A known dectin-1 
receptor activator (WGPD) was used as an internal positive control to confirm the 
selective inhibition of dectin-1 by WGPS. A one-way ANOVA confirmed statistical 
differences P<0.001 between treatment groups. 
 
Figure 9: Mean MRSA recovery per million viable U937 macrophages following treatment with MGN-3 or LPS in the 
absence/presence of the dectin-1 inhibitor WGPS. Error bars represent the standard error of the mean (SEM). * 
represents significant difference compared to the NEG control (P<0.001). n = 24 across for all treatments. 
 
As highlighted in section 3.3, MRSA recovery significantly (P<0.001) decreased with 
following treatment of U937 macrophages with MGN-3 or LPS. 
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The addition of the dectin-1 inhibitor (WGPS) significantly (P<0.001) inhibited the 
clearance of MRSA induced by MGN-3 or LPS. The mean MRSA recovery per million 
viable macrophages for 0.5, 1.0 and 2.0 mg/ml MGN-3 increased from 312, 233 and 154 
CFU/ml in the absence of WGPS to 675, 475 and 422 CFU/ml in the presence of WGPS 
respectively.  Similarly, mean MRSA recovery per million viable macrophages for 1.0 and 
5.0 µg/ml LPS increased substantially from 92 and 41 CFU/ml in the absence of WGPS 
to 428 and 298 CFU/ml in the presence of WGPS respectively.  
Treatment of U937 macrophages with WGPS alone (733 CFU/ml) resulted in a non-
significant (P>0.05) decrease in phagocytic function compared to the NEG control (576 
CFU/ml), confirming the significant reversal of MGN-3/LPS-induced phagocytosis by 
WGPS were real effects and not just an artefact of WGPS on macrophages.  Moreover, 
WGPS significantly (P<0.001) reversed the effects of WGPD, a known dectin-1 receptor 
activator, increasing MRSA recovery from 376 CFU/ml (WGPD) to 635 CFU/ml (WGPD + 
WGPS).  
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3.6 Scanning electron microscopy (SEM) to visualise the effect of MGN-3 & 
LPS on phagocytosis of MRSA 
Host-pathogen interaction using untreated macrophages (Figure 10; Panels 1A and 1B) 
showed MRSA as small (≤1 µm) spherical cells engaging with lamellipodia-producing 
macrophages, indicative of phagocytosis. 
  
  
  
Figure 10: SEM of host-pathogen interactions of untreated U937 macrophages with MRSA at a magnification of 
10,000x (1A) and 25,000x (1B).  Host-pathogen interactions of MGN-3 treated U937 macrophages with MRSA were 
captured at magnifications of 10,000x (2A) and 25,000x (2B). Host-pathogen interactions of LPS-treated U937 
macrophages with MRSA were captured at magnifications of 10,000x (3A) and25,000x (3B).  Scale bars indicate 1 µm. 
The red circles show a single MRSA bacterium engaging with the U937 macrophage. The red arrow indicates the 
formation of a lamellipodium. 
 
1A 1B 
2A 2B 
3A 3B 
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The U937 macrophages treated with 2.0 mg/ml MGN-3 (Figure 10; Panels 2A and 2B) 
showed increased lamellipodia formation and interaction with MRSA compared to the 
untreated macrophages. LPS-treated macrophages (Figure 10; Panels 3A and 3B) 
resulted in visibly more engagement with MRSA in comparison to the untreated and 
MGN-3 treated macrophages, however it shows a decrease in lamellipodia formation 
compared to MGN-3 treated cells.  
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4. Discussion 
This study determined the effect of MGN-3 on the clearance of MRSA by human U937 
macrophages, and possible mechanisms of action of MGN-3 on phagocytes.  The 
internalisation of MGN-3 was assessed by a colorimetric assay and then visually 
confirmed by confocal microscopy, using a fluorescent (GFP-tagged) antibody specific 
for AX. To study the potential mechanism of action of MGN-3, the involvement of 
specific receptors (TLR-4 and dectin-1) was interrogated by pharmacological receptor 
inhibition. Finally, to visualise the findings, SEM was used to show host-pathogen 
interaction. 
 
4.1 MGN-3 internalisation 
The internalisation of MGN-3 by U937 macrophages was confirmed via two independent 
assays (Section 3.2); the phloroglucinol colorimetric assay (Douglas, 1981) to detect 
intracellular xylose, and by intracellular detection of AX by confocal microscopy using an 
AX specific fluorescently-labelled antibody.  This independent confirmation of MGN-3 
uptake by phagocytes such as macrophages, provides a mechanistic route by which 
MGN-3 may induce phagocytosis. 
Receptor-mediated endocytosis and pinocytosis (both of which are actin polymerisation 
independent mechanisms), together with phagocytosis are some of the cellular 
processes that are likely to lead to MGN-3 internalisation (McCann et al., 2005). 
However, a study on the internalisation of b-glucan by RAW murine macrophages 
indicated that internalisation is not essential for inducing inflammatory responses 
(McCann et al., 2005), suggesting only interaction with surface receptors is necessary. 
Consequently, further research is required to understand whether MGN-3 
internalisation is essential to illicit phagocytosis, or whether simply activation of cell 
surface receptors alone is sufficient to stimulate MGN-3-induced phagocytosis. 
Previous murine studies have shown that GI macrophages can take up and transport 
orally administered b-glucan (400 µg/day) systemically to the lymph, spleen and bone 
marrow (Hong et al., 2004). The uptake of MGN-3 shown in the current study may 
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suggest that MGN-3 could be transported through the intestinal lumen by GI 
macrophages, to modulate immune responses both locally and systemically. 
The data in section 3.2.1 showed the percentage uptake of MGN-3 by U937 
macrophages to be approximately 29%. This is suggestive that the majority of the total 
available MGN-3 may act on extracellular macrophage receptors to illicit immune 
responses.  
 
4.2 MGN-3 and its effect on phagocytosis of MRSA 
The flow cytometry results (Figures 4, 5) confirmed the generation of CD11c positive 
macrophages in concordance with the findings of Sproston et al. (2018). 
MGN-3 at several concentrations (0.5, 1.0 and 2.0 mg/ml) was used to determine its 
effect on macrophage-mediated phagocytosis of MRSA. The results (Figure 7) showed 
significant dose-dependent clearance of MRSA in the presence of MGN-3, indicating 
MGN-3 is effective stimulator of macrophage phagocytosis. This suggests MGN-3 may 
be used to stimulate innate host (human) responses during MRSA infection, and 
potentially reduce the over-reliance on antibiotics in the treatment of MRSA infections 
in patients. 
Host-pathogen interaction with MRSA was confirmed by SEM (Figure 10), which showed 
that MGN-3 and LPS induced the formation of lamellipodia and increased macrophage 
bacterial interaction. Lamellipodia are critically involved in the process of bacterial 
engulfment and phagocytosis (Veale et al., 2011). This further suggests that MGN-3 can 
enhance inflammatory processes in response to MRSA infection.  
The results from this study mirror previous studies showing MGN-3 augments 
phagocytic ability in vitro (Ghoneum and Matsuura, 2004), with MGN-3 enhancing 
phagocytosis in a dose dependant manner. For example, significant NK cell activation 
was detected following treatment with MGN-3 at concentrations ³ 100 µg/ml 
(Ghoneum and Matsuura, 2004).  
Similar studies have investigated the enhancement of phagocytosis by natural agents. A 
study published in 2010 suggested that green tea polyphenols (pyrogallol-type) enhance 
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the phagocytic activity of 1,25-dihydroxyvitamin D3 (VD-3) differentiated HL60 cells 
through caspase signalling (Monobe et al., 2010). An ex vivo study using female Balb/c 
mice indicated that garlic extract has the ability to activate macrophages, and augment 
phagocytosis in response to parasitic infection (Ghazanfari et al., 2006). Finally, 
macrophage activation is shown to be modulated by Panax ginseng polysaccharide 
against S. aureus induced sepsis (Lim et al., 2002). 
 
4.3 MGN-3 and its mechanisms of action 
The correlation between biological activities and polysaccharides have been reported 
(Shimada et al., 2012). LPS is a polysaccharide, made of bacterial cell surface 
components, known to stimulate biological activities (Lerouge and Vanderleyden, 2002). 
LPS and AX show similarities in terms of molecular weight (30 – 100 kDa) and general 
structure (Li et al., 2015). This suggests MGN-3, an arabinoxylane polysaccharide, could 
compete for similar receptors/mechanisms as LPS (Ghoneum et al., 2013). TLR-4 is a 
polysaccharide receptor, often associated with LPS, which could be a possible receptor 
for MGN-3 (de Lima et al., 2014; Zhang et al., 2016a).  
MGN-3 and LPS receptor competition, highlighted in section 3.3 (Figure 7), examined 
this concept. The combination of MGN-3 and LPS resulted in an overall increased level 
of phagocytosis compared to the MGN-3 treatment alone, however, it was not as 
effective as LPS alone. The intermediate phagocytic response when MGN-3 was 
combined with LPS suggests they are potentially competing as ligands for the same 
receptor on the U937 macrophage. This indicates that during infection, MGN-3 could 
potentially act to modulate some of the more detrimental pro-inflammatory (non-
phagocytic) responses caused by LPS, warranting further investigation in this area. 
 
 TLRs and their role in MGN-3-induced phagocytosis 
TLR-4 is a known receptor for LPS (Fang et al., 2017). A receptor inhibitor was used in 
this study to uncover the involvement/contribution of TLR-4 to the activity of MGN-3. 
The results in section 3.4 (Figure 8) revealed a complete reversal of the effects of both 
MGN-3 and LPS with the addition of the TLR-4 inhibitor, which shows that both 
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molecules act on the same receptor. This suggests that TLR-4 may play a significant 
mechanistic role in the phagocytic effects of MGN-3. TLR-4 is known to recognise gram-
negative bacterial LPS and DAMPs, leading to cytokine production and inflammation 
(Molteni et al., 2016; Fang et al., 2017). As suggested in section 1.6.1, MGN-3/TLR-4 
engagement could activate the MyD88-dependant and/or the TRIF-dependant 
pathways, resulting in phagocytosis. 
The TLR family is known for their high affinity for polysaccharides, suggesting other 
receptors from this family could be involved in MGN-3-mediated activity (Chen et al., 
2009). For example, TLR-1, 2 and 6 recognise PAMPs such as mannan (Kawasaki and 
Kawai, 2014). Mannan is polysaccharide and a polymer of D-mannose which is a sugar, 
and like arabinoxylan, the sugars are linked together by b-1,4 glycosylic bonds (Moreira 
and Filho, 2008). These similarities in polysaccharide structure could potentially suggest 
that these three receptors could also recognise MGN-3 molecules. 
 
 Dectin-1 and its role in MGN-3 induced phagocytosis 
Dectin-1 is a C-type lectin receptor, located on macrophages, neutrophils and dendritic 
cells that can initiate inflammatory responses such as phagocytosis and respiratory burst  
(Ma and Underhill, 2013). Dectin-1 has been identified as a PRR for b-glucan (Herre et 
al., 2004). 
MGN-3 contains b-glucan, polysaccharides that are produced by fungi, yeast and many 
plants (H. S. Kim et al., 2011). The biological activities of b-glucan are dependent on its 
molecular weight, with inactivity frequently seen in smaller molecules (below 5,000 – 
10,000 Da) (H. S. Kim et al., 2011). This suggests that the biological activity of MGN-3 
could be down in part to the presence of b-glucan. 
The results in section 3.5 (Figure 9) revealed that the phagocytosis induced by MGN-3 
was significantly suppressed by the addition of a dectin-1 receptor inhibitor. This finding 
suggests that MGN-3 may also be acting in part through the dectin-1 receptor to 
promote phagocytosis. Dectin-1 is predominantly involved in antifungal immunity, along 
with other C-type lectin receptors, but is also involved in the recognition of bacteria and 
viruses (Drummond and Brown, 2011). Upon receptor engagement, spleen tyrosine 
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kinase (Syk) is activated leading ultimately to the initiation of NF-kB and MAPK via a 
signalling cascade (Kimura et al., 2014). Dectin-1 can initiate the production of lipid 
mediators and cytokines such as TNFa, IL-6 and IL-10 (Drummond and Brown, 2011).  
The dectin-1 receptor has been shown to be expressed on mast cells in humans and 
mice, which are related to allergic reactions and hypersensitivity (Kimura et al., 2014). 
This suggests that MGN-3 may also mediate inflammatory responses in cases of allergy 
and hypersensitivity.  
 
 Other mechanisms of action 
In summary, the data from this study suggest MGN-3 may act on multiple receptors 
including TLR-4 and dectin-1 (Figure 11). However, other receptors may also recognise 
MGN-3. Another PRR receptor that may also be involved is complement receptor CR3, 
also known as CD11b (Chen et al., 2009). CD11b is a phagocytic receptor expressed on 
the surface of cells, including macrophages and dendritic cells (Kang et al., 2016). CD11b 
is a specific receptor for b-glucan in macrophages for opsonized polysaccharides (Chen 
et al., 2009) so may also contribute to the biological activity of MGN-3. The mannose 
receptor is known to recognise carbohydrate structures and is a PRR in the C-type lectin 
family, found on the surface of several cell types including macrophages and dendritic 
cells  (Li et al., 2017). The mannose receptor plays an important role in macrophage 
phagocytic function, cytokine and ROS secretion (Li et al., 2017). It is unknown whether 
the mannose receptor could recognise the carbohydrate structures of MGN-3 and 
promote phagocytosis, thus warranting further investigations using a mannose receptor 
inhibitor. 
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Figure 11: MGN-3 and LPS stimulates both TLR-4 and Dectin-1 promoting phagocytic clearance of MRSA. TLR-4 
engagement activates the myeloid differentiation factor 88 (MyD88)-dependant pathway and the TIR domain-
containing adaptor inducing interferon-beta (TRIF)-dependant pathway, leading to nuclear factor kappa B (NF-kB) 
and mitogen-activated protein kinase (MAPK) activation. Dectin-1 engagement leads to spleen tyrosine kinase (Syk) 
activation which causes nuclear factor kappa B (NF-kB) and mitogen-activated protein kinase (MAPK) activation. This 
all leads to phagocytosis.  
 
4.4 Clinical impacts of MGN-3/AX 
Dietary fibre consumption is associated with human health benefits, including the 
reduced risk of diabetes and cardiovascular disease development (Mendis et al., 2016). 
AX is a primary source of dietary fibre found in cereal grains such as corn, wheat and 
barley, whilst MGN-3 is a widely used nontoxic food supplement (Lattimer and Haub, 
2010; Ooi et al., 2017). The data in this study suggest that increased consumption of 
these food groups/supplements may contribute to immune system enhancement 
leading to enhanced pathogen clearance. Previous studies have suggested that dietary 
fibre can enhance the protective potential of the GI mucosal barrier (Brownlee, 2011). 
The human intestine constantly encounters foreign antigens (Bain and Mowat, 2014), 
and MGN-3-induced enhancement of the mucosal barrier could inhibit systemic entry 
of possible pathogens. Studies have shown that AX such as MGN-3 can modulate 
systemic immune responses (section 1.5.1), not just local immune activity in the gut 
(Lissoni et al., 2008). This suggests that MGN-3 could act to enhance systemic phagocyte 
activity before and after infection presents. 
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Additional studies are needed to uncover further mechanisms of action of MGN-3 and 
its clinical impact. However, the current results suggest that MGN-3 may be used as a 
potential therapy for MRSA treatment, or in conjunction with antibiotics to promote a 
reduction in antibiotic usage. 
 
4.5 Future work 
Ex vivo testing on healthy human participants could be performed to confirm if oral 
consumption of MGN-3 can lead to detectable levels of circulating AX in the 
bloodstream. Moreover, its effect on cell activation, differential inflammatory cell 
responses and alteration of inflammatory marker profiles could be examined in 
conjunction with ex vivo phagocytosis assays. This could improve knowledge on the 
mechanisms of action of MGN-3 in humans. 
Other phagocytes such as dendritic cells or macrophages derived from human 
peripheral blood monocytes (HPBM), could be tested to see if the findings can be 
reproduced in other cell types (including human primary macrophages) following MGN-
3 stimulation. Confirmation of the findings in other cell types would provide a body of 
evidence to support the receptors involved in the phagocytic activity of MGN-3.  
Further research to explore the precise mechanisms of action of MGN-3, including 
investigating additional cell surface receptors such as the CD11b complement receptor, 
is also required to highlight potential therapeutic strategies to promote the clearance of 
bacterial infections. This may be of importance in the search for new therapies for the 
treatment of MRSA. 
Inhibiting macrophage uptake of MGN-3 by particle uptake antagonists such as 
cytochalasin D (McCann et al., 2005), can be used to gain further insight into the effects 
of MGN-3 internalisation. 
Finally, other clinically relevant bacteria such as vancomycin-resistant enterococci and 
Pseudomonas aeruginosa could be tested to examine phagocytosis by MGN-3 
stimulated macrophages. 
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5. Conclusion 
In conclusion, this study established that MGN-3 significantly promotes phagocytosis of 
MRSA by U937 macrophages. In addition, TLR-4 and dectin-1 receptor inhibitors 
supressed the phagocytic actions of MGN-3, implicating both these receptors contribute 
at least in part to the mechanisms of action of MGN-3. Additional research is urgently 
needed to explore these receptor-mediated mechanisms in further detail and identify 
any further contributing mechanisms by which MGN-3 stimulates bacterial clearance. 
Such studies may ultimately lead to the development of targeted dietary 
supplements/treatments that promote innate immunity and combat bacterial 
infections, such as MRSA, without sole reliance on antibiotics. Such inexpensive and 
relatively safe dietary-based therapies would reduce the substantial costs incurred by 
healthcare providers to treat problematic bacterial infections such as MRSA. Moreover, 
reduced reliance on antibiotics would be a beneficial strategy to limit the spread of 
antibiotic resistance associated with pathogens such as MRSA.  
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